OnkoSight Myeloid Seq OnkoMyelo

Synonyms

Allscripts (AEHR) Order Name

OnkoSight Myeloid Seq.

Sunrise Clinical Manager (SCM) Order Name

OnkoSight Myeloid Disorder Panel

EPIC Order Name

OnkoSight Myeloid Seq.

Clinical Info

This test is used to aid diagnosis, prognostic risk assessment and therapeutic selection in various myeloid and lymphoid malignancies.
This test includes the following genes: ABL1, ANKRD26, ARID1A, ASXL1, ATM, ATRX, B2M, BCL2, BCL6, BCOR, BCORL1, BIRC3, BRAF, BRCC3, BTK, CALR, CARD11, CBL, CBLB, CBLC, CCND1, CCND3, CD274, CD79A, CD79B, CDK4, CDKN1B, CDKN2A, CDKN2B, CEBPA, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CSNK1A1, CTCF, CUX1, CXCR4, DDX41, DKC1, DNMT3A, EBF1, ELANE, EP300, ERG, ETNK1, ETV6, EZH2, FAS, FBXW7, FGFR1, FGFR3, FLT3, FOXO1, GATA1, GATA2, GNA13, GNAS, GNB1, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, IRF4, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MALT1, MAP2K1, MAPK1, MED12, MEF2B, MPL, MYC, MYD88, NF1, NFE2, NOTCH1, NOTCH2, NPM1, NRAS, NSD2, NT5C2, P2RY8, PAX5, PDCD1, PDGFRA, PHF6, PIGA, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIM1, PLCG2, PML, POT1, PPM1D, PRDM1, PRPF8, PTEN, PTPN11, RAD21, RB1, RHOA, RIT1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SMC1A, SMC3, SOCS1, SRSF2, STAG2, STAT3, STAT5B, STAT6, TCF3, TERC, TERT, TET2, TNFAIP3, TNFRSF14, TP53, U2AF1, WT1, UBA1, XPO1 and ZRSR2.

Specimen Type

Blood, Bone Marrow

Specimen Volume

Volume
3-5 mL (blood), 1-2 mL (bone marrow)
Minimum Volume
3 mL (blood), 1 mL (bone marrow)

Container

Specimen:
Whole blood, bone marrow, cell pellets from whole blood or cell suspension
Container:
Lavender-top (EDTA) tube; green-top (sodium heparin) tube; cells left over from flow cytometry analysis,
either fresh cell suspension or fresh/frozen cell pellet spun down from suspension.
Cell suspension should be shipped on ice.

Collection Instructions

Causes for Rejection
Specimen does not meet criteria for sample type, container, minimum volume, collection and storage; frozen whole blood or marrow; 
leaking tube; clotted blood or marrow; grossly hemolyzed specimen or otherwise visibly degraded; contaminated specimen; 
contains suspicious foreign material

Transport Instructions

Room Temperature

Specimen Stability

Methodology

Pan-Heme NGS assay utilizes capture-based next-generation sequencing of whole genomic DNA libraries to identify gene alterations
that have diagnostic, prognostic and therapeutic significance in hematologic malignancies.

Days Performed

TAT: 10 - 14 Days

Performing Laboratory

Labcorp

CPT

81450

PDM

1659893

Result Interpretation

Forms